Novartis has launched its TOBI Podhaler tobramycin dry powder inhaler in the UK. The DPI, for the treatment of P. aeruginosa infections in cystic fibrosis patients. The CF Trust responded to the launch on its website, noting “This is the first ever antibiotic pod haler and is a development the CF Trust welcomes.”
Read a brief article.
published on
Featured event:
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
